Citation Impact
Citing Papers
Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability
2016 Science
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
EglN2 associates with the NRF 1‐ PGC 1α complex and controls mitochondrial function in breast cancer
2015 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
2009
EGFR Antagonists in Cancer Treatment
2008 Standout
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
2011
PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment
2009
Dasatinib
2009
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Therapeutic cancer vaccines: are we there yet?
2010
Enzyme-Catalyzed Activation of Anticancer Prodrugs
2004
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
2015
Dynamics of tumour angiogenesis: Effect of razoxane-induced growth rate slowdown
2003
Does Adjuvant Chemoradiotherapy Improve the Prognosis of Gastric Cancer After an R1 Resection? Results from a Dutch Cohort Study
2014
Prodrug Strategies in Anticancer Chemotherapy
2007
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
2001
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Two-component molecular tagging velocimetry utilizing NO fluorescence lifetime and NO_2 photodissociation techniques in an underexpanded jet flowfield
2009
Entanglement of bosonic modes through an engineered exchange interaction
2019 StandoutNatureNobel
Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production
2013
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Colorectal cancer
2013 Standout
Engineering an allosteric transcription factor to respond to new ligands
2015 StandoutNobel
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
2012
Colorectal cancer
2019 Standout
Exploiting tumour hypoxia in cancer treatment
2004 Standout
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Going viral with cancer immunotherapy
2014
Casiopeina III-ia induces apoptosis in HCT-15 cells in vitro through caspase-dependent mechanisms and has antitumor effect in vivo
2007
Angiogenesis in life, disease and medicine
2005 StandoutNature
Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
2002
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
EMT: 2016
2016 Standout
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
2013
Gastric cancer
2020 Standout
Characterizing entanglement of an artificial atom and a cavity cat state with Bell’s inequality
2015
Small cell lung cancer: the importance of the extracellular matrix
2004
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial
2017
Antiangiogenic therapy in oncology: current status and future directions
2016
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2013
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
2011
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner
2012 StandoutNobel
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Antibacterial drug discovery in the resistance era
2016 StandoutNature
Advances in Malignant Mesothelioma
2005 Standout
Pericytes and vessel maturation during tumor angiogenesis and metastasis
2010
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
2007
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Cancer of the Ovary
2004 Standout
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
2009
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
2000
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis
2010
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
2011
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Dialogue between E. coli free radical pathways and the mitochondria of C. elegans
2015 StandoutNobel
Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer
2005
Clinical Features of Hypersensitivity Reactions to Carboplatin
1999
Fluorescence Lifetime Measurements and Biological Imaging
2010 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
A Schrödinger cat living in two boxes
2016 StandoutScienceNobel
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.
2001
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
2020 Standout
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma
2004
Ongoing trials with matrix metalloproteinase inhibitors
2000
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer
2004
Works of Mark Saunders being referenced
Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
2012
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
2010
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects.
1999
NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line
2000
Management of advanced colorectal cancer: state of the art
2006
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
1999
Genome Scale Reconstruction of a Salmonella Metabolic Model
2009
Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis
2005
A Novel Cyclic Adenosine Monophosphate Analog Induces Hypercalcemia via Production of 1,25-Dihydroxyvitamin D in Patients with Solid Tumors
1997
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study
2017
Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours
2002
Hypersensitivity reactions to cisplatin and carboplatin — A report on six cases
1992
The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions
2000
A Phase I–II Study of Postoperative Capecitabine-Based Chemoradiotherapy in Gastric Cancer
2007
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
2013
A Phase II Study of Weekly Cisplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer: Is This a Strategy Still Worth Pursuing?
2005
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study
2009
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis
2015
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
1999
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
2000
Dependence of the nascent vibrational distribution of NO(v) on the photolysis wavelength of NO2 in the range λ = 266–327 nm measured by time-resolved Fourier transform infrared emission
2007
Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume
2004
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial
2006
Bell-inequality tests with entanglement between an atom and a coherent state in a cavity
2012